Buscar
Vir Biotechnology Inc
VIRAñadir a la lista de seguimiento
8.660USD
-0.240-2.70%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
1.46BCap. mercado
PérdidaP/E TTM
Más Datos de Vir Biotechnology Inc Compañía
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Información de Vir Biotechnology Inc
Símbolo de cotizaciónVIR
Nombre de la empresaVir Biotechnology Inc
Fecha de salida a bolsaOct 11, 2019
Director ejecutivoDe Backer (Marianne)
Número de empleados408
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 11
Dirección1800 Owens Street
CiudadSAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94158
Teléfono14159064324
Sitio Webhttps://www.vir.bio/
Símbolo de cotizaciónVIR
Fecha de salida a bolsaOct 11, 2019
Director ejecutivoDe Backer (Marianne)
Ejecutivos de Vir Biotechnology Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
233.10K
-15.93%
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
40.66K
+19.68%
Mr. Jeffrey S. (Jeff) Hatfield
Mr. Jeffrey S. (Jeff) Hatfield
Independent Director
Independent Director
31.81K
+25.15%
Dr. Norbert W. Bischofberger, Ph.D.
Dr. Norbert W. Bischofberger, Ph.D.
Independent Director
Independent Director
18.67K
+42.86%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
14.62K
--
Ms. Vanina De Verneuil, J.D.
Ms. Vanina De Verneuil, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
8.22K
-321.82%
Dr. Vicki L. Sato, Ph.D.
Dr. Vicki L. Sato, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. C. Elliott Sigal, M.D., Ph.D.
Dr. C. Elliott Sigal, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Janet Napolitano, J.D.
Ms. Janet Napolitano, J.D.
Independent Director
Independent Director
--
--
Dr. Mark Eisner, M.D.
Dr. Mark Eisner, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
233.10K
-15.93%
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
40.66K
+19.68%
Mr. Jeffrey S. (Jeff) Hatfield
Mr. Jeffrey S. (Jeff) Hatfield
Independent Director
Independent Director
31.81K
+25.15%
Dr. Norbert W. Bischofberger, Ph.D.
Dr. Norbert W. Bischofberger, Ph.D.
Independent Director
Independent Director
18.67K
+42.86%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
14.62K
--
Ms. Vanina De Verneuil, J.D.
Ms. Vanina De Verneuil, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
8.22K
-321.82%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Vir Biotechnology Inc?
Los cinco principales accionistas de Vir Biotechnology Inc son: Dr. Marianne De Backer, Ph.D.
¿Cuántas instituciones poseen acciones de Vir Biotechnology Inc (VIR)?
A fecha de 2026Q1, 497 instituciones poseen acciones de Vir Biotechnology Inc, con un valor de mercado combinado de aproximadamente 130.35M, lo que representa el 77.29% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 9591956.00.